Fundraising FoxBiotech Startups
11,136 companies tagged Biotech, with their investors and founders.
0 investors
QuickTake Health builds self-service health assessment kiosks that automate vital sign capture using biometric sensors, camera technology, and facial recognition, syncing data to electronic health record systems. It serves senior living communities, athletic programs, health clubs, and care providers.
0 investors
0 investors
Qureator develops non-animal testing methods for drug development, notably achieving an FDA IND approval without animal proof-of-concept data in collaboration with SillaJen. The company works in preclinical biotech, providing alternatives to animal testing for pharmaceutical partners.
0 investors
0 investors
0 investors
0 investors
Rafael Holdings is a publicly traded (NYSE: RFL) company focused on the discovery and development of oncology therapeutics through a wholly-owned portfolio of companies, with multiple clinical programs including two Phase 3 trials. It is transitioning from a clinical-stage company toward a commercial pharmaceutical enterprise.
0 investors
0 investors
0 investors
Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for biologics and drugs, primarily through its proprietary RaniPill capsule platform, which comes in two configurations (RaniPill GO for up to 3 mg microtablet doses and RaniPill HC for up to 200µL liquid doses). The company is advancing a pipeline of oral therapeutic candidates internally and through collaborations with third-party biopharmaceutical companies, including RT-114 (a GLP-1/GLP-2 dual agonist for obesity) in Phase 1 trials and RT-117 (an antibody for hemophilia) in collaboration with Chugai Pharmaceutical.
0 investors
0 investors
0 investors
0 investors
0 investors
Ravgen develops noninvasive prenatal genetic testing, using DNA-based methods to detect fetal genetic conditions such as Down's syndrome from a maternal blood sample. It serves pregnant patients seeking prenatal diagnostic information without the miscarriage risk of invasive procedures.
0 investors
0 investors
ReAlta Life Sciences develops pegtarazimod, a drug candidate that modulates upstream inflammatory pathways (neutrophils and complement) and is in Phase 2 clinical trials for neonatal Hypoxic Ischemic Encephalopathy (HIE). The compound is positioned as a platform asset with potential applications across multiple inflammatory diseases.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors